home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Biogenerics and new technologies compete with 1st generation major protein products

 
  June, 19 2006 11:18
your information resource in human molecular genetics
 
     
BARCELONA, Spain | June 19, 2006 | The Business Intelligence firm La Merie S.L. reported today that the US$ 32 bln market of major protein products with commencing patent expiry is endangered by generic products and by innovator solutions including engineered molecules and drug delivery solutions. Examples are the first biogeneric somatotropin now approved in the US and the European Union and Pfizer’s inhaled insulin. Both examples mark the entry of new players into the lucrative human growth hormone (hGH) and insulin markets. More hGH biogeneric products including slow release formulations are approaching the US$ 2.3 bln market and lead to erosion and conversion from an innovator to a biogeneric market.

Although estimated price cuts of 25 to 30 % will be less than those for small molecule generics, cost pressure in the health care markets will support acceptance of biogeneric products. The US$ 11.2 bln erythropoietin market will face tough competition by consolidated biogeneric manufacturers. Numerous drug delivery solutions and protein engineering approaches are filling the pipelines with interferon, G-CSF, insulin and FSH products. These results and more were found in a search conducted by La Merie Business Intelligence. The competitor analysis can be acquired at www.pipelinereview.com, La Merie’s News Center and Online Store. More information will be provided in the Biogenerics miniseries published in the FREE daily R&D Newsletter of PipelineReview.com beginning June 19 .

The competitor analysis covers the field of eight product families: erythropoietin, human growth hormone, interferon, insulin, G-CSF, follicle stimulating hormone, thrombopoietin (TPO) agonists and thrombolytics. The pipeline evaluation includes the market description of the first generation products and a compilation of next generation projects, drug delivery solutions, protein engineering approaches, orally available small molecules and biogeneric projects in Western countries as well as in countries with insufficient patent protection.

About FREE R&D Newsletter

The daily Newsletter from Europe provides a selection of the most interesting news from biopharmaceutical R&D and information about partnering opportunites and company profiles. Sign up for a free copy of the R&D Newsletter at www.pipelinereview.com/newsletter

About PipelineReview.com

PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on R&D in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. For more information visit www.pipelinereview.com.

About La Merie

La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.


Message posted by: Jorge Márquez

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.